Outcomes in Patients With ST-Segment Elevation Acute Myocardial Infarction Treated With Clopidogrel Versus Prasugrel (from the INFUSE-AMI Trial)

Prasugrel is more potent than clopidogrel, but it is not known whether this translates into clinical benefit in patients undergoing primary percutaneous coronary intervention (PCI) with bivalirudin for ST elevation myocardial infarction. In the Intracoronary Abciximab and Aspiration Thrombectomy in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 2014-05, Vol.113 (9), p.1457-1460
Hauptverfasser:	Brener, Sorin J., MD, Oldroyd, Keith G., MD, Maehara, Akiko, MD, El-Omar, Magdi, MD, Witzenbichler, Bernhard, MD, Xu, Ke, PhD, Mehran, Roxana, MD, Gibson, C. Michael, MD, Stone, Gregg W., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Antithrombins - therapeutic use Cardiovascular Coronary Angiography Electrocardiography Female Hirudins Humans Male Middle Aged Myocardial Infarction - drug therapy Myocardial Infarction - physiopathology Myocardial Infarction - surgery Peptide Fragments - therapeutic use Percutaneous Coronary Intervention Piperazines - therapeutic use Platelet Aggregation Inhibitors - therapeutic use Prasugrel Hydrochloride Purinergic P2Y Receptor Antagonists - therapeutic use Recombinant Proteins - therapeutic use Thiophenes - therapeutic use Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!